INDICATION
LEMTRADA is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

IMPORTANT SAFETY INFORMATION
WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES
- LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane (anti-GBM) disease. Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts at periodic intervals for 48 months after the last dose of LEMTRADA.
- LEMTRADA causes serious and life-threatening infusion reactions. LEMTRADA must be administered in a setting with appropriate equipment and personnel to manage anaphylaxis or serious infusion reactions. Monitor patients for two hours after each infusion. Make patients aware that serious infusion reactions can also occur after the 2-hour monitoring period.
- Serious and life-threatening stroke (including ischemic and hemorrhagic stroke) has been reported within 3 days of LEMTRADA administration. Instruct patients to seek immediate medical attention if symptoms of stroke occur.
- LEMTRADA may cause an increased risk of malignancies, including thyroid cancer, melanoma, and lymphoproliferative disorders. Perform baseline and yearly skin exams.
- Because of the risk of autoimmunity, infusion reactions, and malignancies, LEMTRADA is available only through restricted distribution under a Risk Evaluation and Mitigation Strategy (REMS) Program. Call 1-855-676-6326 to enroll in the LEMTRADA REMS Program.

CONTRAINDICATIONS
LEMTRADA is contraindicated in patients who are infected with Human Immunodeficiency Virus (HIV) because LEMTRADA causes prolonged reductions of CD4+ lymphocyte counts.

WARNINGS AND PRECAUTIONS
- Autoimmunity: Treatment with LEMTRADA can result in the formation of autoantibodies and increase the risk of autoimmune-mediated conditions, including serious autoimmune conditions. Measure the urine protein to creatinine ratio prior to initiation of treatment. Obtain complete blood counts with differential, serum creatinine levels, and urinalysis with cell counts before starting treatment and then monitor at monthly intervals until 48 months after the last dose of LEMTRADA, or longer, if clinically indicated.
- Infusion Reactions: LEMTRADA causes cytokine release syndrome resulting in infusion reactions. In clinical studies, 92% of LEMTRADA-treated patients experienced infusion reactions. Serious reactions occurred in 3% of these patients and included anaphylaxis in 2
patients (including anaphylactic shock), angioedema, bronchospasm, hypotension, chest pain, bradycardia, tachycardia (including atrial fibrillation), transient neurologic symptoms, hypertension, headache, pyrexia, and rash. In some patients, infusion reactions were reported more than 24 hours after LEMTRADA infusion. Postmarketing cases of pulmonary alveolar hemorrhage have been reported with onset within 48 hours of LEMTRADA infusion. Cases of severe, including fatal, neutropenia have been reported within 2 months of LEMTRADA infusion. Mild to moderate decreases in platelet counts, starting at the time of alemtuzumab infusion have been reported.

Premedicate patients with corticosteroids immediately prior to LEMTRADA infusion for the first 3 days of each treatment course. Consider pretreatment with antihistamines and/or antipyretics. Infusion reactions may occur despite pretreatment.

LEMTTRA can only be administered in certified healthcare settings that have on-site access to equipment and personnel trained to manage infusion reactions (including anaphylaxis and cardiac and respiratory emergencies).

- **Stroke and Cervicocephalic Arterial Dissection:** In the postmarketing setting, serious and life-threatening stroke has been reported within 3 days of LEMTRADA administration, with most cases occurring within 1 day.

In the postmarketing setting, cases of cervicocephalic arterial dissection involving multiple arteries have been reported within 3 days of LEMTRADA administration.

Educate patients on the symptoms and instruct patients to seek immediate medical attention if symptoms of stroke or cervicocephalic arterial dissection occur.

- **Malignancies:** LEMTRADA may cause an increased risk of malignancies, including thyroid cancer, melanoma, and lymphoproliferative disorders. Monitor for symptoms of thyroid cancer. Perform baseline and yearly skin exams. Because LEMTRADA is an immunomodulatory therapy, caution should be exercised in initiating LEMTRADA in patients with pre-existing or ongoing malignancies.

- **LEMTTRA REMS Program:** Only prescribers, patients, pharmacies and healthcare facilities certified and enrolled in the REMS program can prescribe, receive, dispense or administer LEMTRADA.

- **Immune thrombocytopenia (ITP)** occurred in 2% of LEMTRADA-treated patients in clinical studies in MS. One LEMTRADA-treated patient developed ITP that went unrecognized prior to the implementation of monthly monitoring requirements, and died from an intracerebral hemorrhage. ITP has been diagnosed more than 3 years after the last LEMTRADA dose. If ITP is confirmed, promptly initiate medical intervention.

- **Glomerular nephropathies,** including anti-GBM disease, occurred in 0.3% of LEMTRADA-treated patients in MS clinical trials and have been diagnosed up to 40 months after the last dose of LEMTRADA. In postmarketing cases, some LEMTRADA-treated patients with anti-GBM disease developed end-stage renal disease requiring dialysis or renal transplantation. Urgent evaluation and treatment is required, because early detection and treatment of nephropathies can improve the preservation of renal function and may decrease the risk of poor outcomes. Anti-GBM disease can be life-threatening if left untreated. Alveolar hemorrhage, manifested as hemoptyis, is a common component of anti-GBM disease and has been reported
in postmarketing cases. Increased serum creatinine with hematuria or signs of pulmonary involvement of anti-GBM disease warrant immediate evaluation. Patients and caregivers should be instructed to seek medical advice if they have concerns.

- **Thyroid endocrine disorders**, including autoimmune thyroid disorders, occurred in 36.8% of LEMTRADA-treated patients in MS clinical studies. Newly diagnosed thyroid disorders occurred throughout the uncontrolled clinical study follow-up period, more than 7 years after the first LEMTRADA dose. Serious thyroid events occurred in 5.2% of patients and included cardiac and psychiatric events. In LEMTRADA-treated patients, 3.8% underwent thyroidectomy. Thyroid disease poses special risks in women who are pregnant. In patients with an ongoing thyroid disorder, LEMTRADA should be administered only if the potential benefit justifies the potential risks. Obtain thyroid function tests prior to initiation of treatment and every 3 months until 48 months after the last infusion, or longer, if clinically indicated.

- **Other autoimmune cytopenias** occurred in LEMTRADA-treated patients in MS clinical trials, including neutropenia, hemolytic anemia, and pancytopenia. One LEMTRADA-treated patient with autoimmune pancytopenia died from sepsis. Prompt medical intervention is indicated if a cytopenia is confirmed.

- **Autoimmune hepatitis** causing liver injury, including acute liver failure requiring transplant, has been reported in patients in the postmarketing setting. Obtain serum transaminases and total bilirubin levels prior to starting LEMTRADA, periodically until 48 months after the last dose, and promptly upon patient developing signs or symptoms suggestive of hepatic dysfunction. Interrupt or discontinue treatment, as appropriate.

- **Infections** occurred in 71% of LEMTRADA-treated patients compared to 53% of patients treated with interferon beta-1a in clinical studies. Serious infections occurred in 3% of patients treated with LEMTRADA as compared to 1% of patients treated with interferon beta-1a. Serious infections in the LEMTRADA group included: appendicitis, gastroenteritis, pneumonia, herpes zoster, and tooth infection.

  - Do not administer live viral vaccines following a course of LEMTRADA, as patients may be at increased risk of infection.
  - Consider delaying LEMTRADA administration in patients with active infection until the infection is fully controlled.
  - Concomitant use of antineoplastic or immunosuppressive therapies could increase the risk of immunosuppression.
  - In the postmarketing setting, serious, sometimes fatal, opportunistic infections have been reported, including aspergillosis, coccidioidomycosis, histoplasmosis, *Pneumocystis jirovecii* pneumonia, nocardiosis and cytomegalovirus infections.
  - *Listeria monocytogenes* infections, including fatal cases of *Listeria* meningoencephalitis, have occurred in LEMTRADA-treated patients. *Listeria* infections have occurred between 3 days to 8 months after taking LEMTRADA. Advise patients to avoid or adequately heat foods that are potential sources for *Listeria monocytogenes*. Initiate these precautions prior to receiving LEMTRADA. Advise patients to watch for symptoms of *Listeria* infection and seek prompt medical help if symptoms occur.
  - Herpes viral infection developed in 16% of LEMTRADA-treated patients compared
to 3% of interferon beta-1a patients. Administer antiviral prophylaxis for herpetic viral infections starting on the first day of each treatment course and continue for a minimum of two months following treatment with LEMTRADA or until CD4+ lymphocyte count is ≥200 cells per microliter, whichever occurs later.

- Cervical human papilloma virus (HPV) infection occurred in 2% of LEMTRADA-treated patients. Annual screening is recommended for female patients.
- Active and latent tuberculosis cases occurred in 0.3% of LEMTRADA-treated patients, most often in endemic regions.
- Fungal infections, especially oral and vaginal candidiasis, occurred in 12% of LEMTRADA-treated patients compared to 3% of interferon beta-1a patients.
- Before initiating LEMTRADA, consider screening patients at high risk of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infection. Carriers of HBV and/or HCV who receive LEMTRADA may be at risk of irreversible liver damage relative to a potential virus reactivation.

- **Acute Acalculous Cholecystitis (AAC):** LEMTRADA may increase the risk of AAC, which occurred in 0.2% of LEMTRADA-treated MS patients compared to 0% of patients treated with interferon beta-1a. Postmarketing cases of AAC have also been reported. Time to onset of symptoms ranged from less than 24 hours to 2 months after LEMTRADA infusion. Typical risk or predisposing factors such as concurrent critical illness were often not reported. AAC is associated with high morbidity and mortality if not diagnosed early and treated. If AAC is suspected, evaluate and treat promptly.

- **Pneumonitis,** including hypersensitivity pneumonitis and pneumonitis with fibrosis, occurred in 0.5% of LEMTRADA-treated patients in clinical studies. Cases of hypersensitivity pneumonitis and pneumonitis with fibrosis occurred in clinical studies. Advise patients to report symptoms of pneumonitis (e.g., shortness of breath, cough, wheezing, chest pain or tightness, and hemoptysis).

- **Drug Products with Same Active Ingredient:** LEMTRADA contains the same active ingredient (alemtuzumab) found in CAMPATH®. If LEMTRADA is considered for use in a patient who has previously received CAMPATH, exercise increased vigilance for additive and long-lasting effects on the immune system.

**Most Common Adverse Reactions**
In controlled clinical trials, the most common adverse reactions (incidence ≥10% and >interferon beta-1a) with LEMTRADA vs interferon beta-1a were: rash (53% vs 6%), headache (52% vs 23%), pyrexia (29% vs 9%), nasopharyngitis (25% vs 19%), nausea (21% vs 9%), urinary tract infection (19% vs 8%), fatigue (18% vs 13%), insomnia (16% vs 15%), upper respiratory tract infection (16% vs 13%), herpes viral infection (16% vs 3%), urticaria (16% vs 2%), pruritus (14% vs 2%), thyroid gland disorders (13% vs 3%), fungal infection (13% vs 4%), arthralgia (12% vs 9%), pain in extremity (12% vs 9%), back pain (12% vs 8%), diarrhea (12% vs 6%), sinusitis (11% vs 8%), oropharyngeal pain (11% vs 5%), paresthesia (10% vs 8%), dizziness (10% vs 5%), abdominal pain (10% vs 5%), flushing (10% vs 4%), and vomiting (10% vs 3%).

**Use in Specific Populations**
Physicians are encouraged to register patients in the pregnancy exposure registry by calling 1-
866-758-2990. Antibodies, including anti-CD52 and autoantibodies, may be transferred from the mother to the fetus during pregnancy. Placental transfer of anti-thyroid antibodies resulting in neonatal Graves’ disease has been reported.

Safety and effectiveness in pediatric patients less than 17 years of age have not been established. Use of LEMTRADA is not recommended in pediatric patients due to the risks of autoimmunity and infusion reactions, stroke, and because it may increase the risk of malignancies.

Please see full Prescribing Information, including Boxed WARNING, for additional Important Safety Information.